DocumentsDate added
Review article
* Sam Straw
Affiliation:-
*Medical student, Scleroderma Research Group, Leeds Institute of Molecular Medicine, St James’ University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
*Corresponding author:
Sam Straw.
Medical student, Scleroderma Research Group, Leeds Institute of Molecular Medicine, St James’ University Hospital, Beckett Street, Leeds, LS9 7TF, UK
Abstract:
Systemic sclerosis (SSc) is a highly heterogeneous disease which would benefit from the adoption of a stratified medicine approach, to improve outcomes for patients and reduce costs to the healthcare system. SSc is orphan of disease activity biomarkers, as the current gold standard prognostic test: the modified Rodnan skin score (MRSS) is flawed. The MRSS has been shown to be unreliable, insensitive to change and not specific in measuring skin fibrosis. Physical measurements of skin thickness, genetic risk factors and autoantibodies may all allow patient stratification, however as proteins are the mediators of biological function; proteomics may offer the best approach. Proteomic studies to identify biomarkers are hypothesized to fulfill the outcome measured in rheumatology (OMERACT) filter criteria of: truth, discrimination and feasibility.
Key words: Stratified medicine; scleroderma; systemic sclerosis; biomarkers; health economics; modified Rodnan skin score; OMERACT; proteomics; autoantibodies; genetic risk factor; skin thickness.
References:
1.Castro S, J.S., Biomarkers in systemic sclerosis. Biomarkers Med 2010;4(1): 133-147.
2. Moon, Ki Won; Song, Ran; Kim, Jin Hyun; Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook. Rheumatology International
2012 August ;32(8); 2465 – 2470. DOI: 10.1007/s00296-011-1993-9.
3.Matucci-Cerinic M, S.V., Nash P, et al., The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology 2009; 48: iii8-iii13.
4.Furst D, K.D., Matucci-Cerinic M, et al., Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007; 34:1194-1200.
5.Czirják L, N.Z., Aringer M, et al., The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66(7):966-969.
6.Chifflot H, F.B., Sordet C, et al., Incidence and Prevalenc of Systemic Sclerosis: A Systemic Literature Review. Semin. Arthritis Rheum 2007; 37(4): 223-235.
7.Abignano G, B.M., Emery P, Del Galdo F, Biomarkers in the management of scleroderma: An update. Curr Rheumatol Rep 2011; 13(4): 4-12.
8.Kaldas M, K.P., Furst D, et al., Sensitivity to change of the moodified Rodnan skin score in diffuse systemic sclerosis - assessment of individual body sites in two large randomized clinical trials. Rheumatology 2009; 48(9):1143-1146.
9.Clements P, L.P.S.J., et al., Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 20(11):1892-1896.
10.Czirják L, F.I., Müller-Ladner U, Skin involvement in systemic sclerosis. Rhuematology (Oxford) 2008; 47(5):44-45.
11.Moinzadeh P, D.C., Ong V, et al., Biomarkers for skin involvement and fibrotic activity in scleroderma. JEADV.
12.Trusheim M, B.E., Douglas F, Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews: Drug Discovery 2007; 6:287-293.
13.B, H., Developing tools for stratified medicine. Nat Rev Drug Discov, 2009; 8(12):919-920.
14.NICE recommends trastuzumab (Herceptin) for advanced breast cancer. 2010 28/12/2010 25/11/2011]; Available from: http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=32318.
15.J, R., Letter from the Editor: stratified medicine. MAbs 2010; 2(2): 107.
16.Chasman J, P.D., Subrahmanyan L, et al., Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291(23): 2821-2827.
17.Bernatsky S, H.M., Panopalis P, et al., The cost of systemic sclerosis. Arthritis and Rheumatism 2009; 61(1):119-123.
18.Boers M, B.P., Strand CV, et al., The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25(2):198-199.
19.Del Galdo F, S.A., Jimenez S, Proteomic analysis identification of a pattern on shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol 2010; 177(4):1638-1645.
20.Ionescu R, R.S., Damjanov N, et al., Repeated teeaching courses of the modified Rodnan skin score in systemic sclerosis. Clin Exp Rheumatol 2010; 28(2):37-41.
21.Furst D, C.P., Steen V, et al., The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25(1): 84-88.
22.Postlewaite A, W.W., Clements P, et al., A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58:1810-1822.
23.Khanna D, C.P., Furst D, et al., Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60:1102-1111.
24.Rohekar G, P.J., Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol 2009; 36(10):2178-2182.
25.Milano A, P.S., Sargent J, et al., Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008; 3(10):e2696.
26.Kissin E, S.A., Gelbard R, et al., Durometry for the assessment of skin disease and systemic sclerosis. Arthritis Rheum 2006; 55(4):603-609.
27.Domsic R, R.-R.T., Lucas M, et al., Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70:104-109.
28.Arnett G, G.P., Shete S, et al., Major histocompatability complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010; 69:822-827.
29.Gorman C, R.A., Zhang Z, et al., Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematous patients and healthy controls. J Immunol 2008; 180:1060-1070.
30.Glas J, S.J., Nagy M, et al., Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS ONE, 2010. 5(e10373).
31.Morgan A, R.J., Conahan P, et al., Evaluation of the rheumatoid arthritis susceptability loci HLA-DRB1, PTPN22, OLIG3/TNFAIP£, STAT4 and TRAF1/C5 in an inception cohort. Arthritis Res Ther 2010; 12(R57).
32.Gorlova O, M.J., Reuda B, et al., Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genet 2011; 7(7): e1002178.
33.V, S., Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum 2005; 35:35-42.
34.Shero J, B.B., Rothfield N., High titers of autoantibodies to topoisomerase I (scl-70) in sera from scleroderma patients. Science 1986; 231:737-740.
35.Czömpöly T, S.D., Czirják L, Antitopoisomerase I autoantibodies in systemic sclerosis. Autoimmun. Rev2009; 8: 692-696.
36.CG., K., Anti-centromere antibodies (ACA). Clin. Rheumatol 1990; 9:S136-S139.
37.Basu D, R.J., Anti-Scl-70. Autoimmunity 2005 38:65-72.
38.LeRoy E, B.C., Fleischmajer R et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
39.Tramposch H, S.C., Senecal J, et al., A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984; 27:121-124.
40.Bargagli E, O.C., Prasse A, et al., Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with intersitital lung diseases. Inflammation, 2008 31:351-354.
41.Rottoli P, M.B., Perari M, et al., Cytokine profile and proteome analysis in bronchoalveolar lavage fluid of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005 5:1423-1430.
42.Giusti L, B.L., Baldini C et al., Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 2007; 34: 2063-2069.
43.Bogatkevich G, L.-B.A., Singleton C, et al., Proteomic analysis of CTGT-activated lung fibroblats: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2008. 295:L603-L611.
44.Aden N, S.X., Aden D, et al., Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology 2008 47: 1754-1760.
45.Carlsson A, W.D., Ingvarsson J, et al., Serum protein profiling of systemic lupus erythematous and systemic sclerosis using recombinant antibody microarrays. Molecular and cellular proteomics 2011; 10(5):M110.005033.
Article citation:
Sam Straw., Stratified medicine approach for systemic sclerosis: state of the art and the need for clinical biomarkers. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35):1754-1762.
Original article
V Sravan Reddy*, I Sarath Chandra, M Pramod Reddy,CM Pavan Kumar Reddy
Affiliation:-
Department of psychiatry,
Mamta General Hospital, Khammam, Andrapradesh-507002, India.
The name of the Department and Institution to which the work should be attributed:-
Department of psychiatry,
Mamta General Hospital, Khammam, Andrapradesh-507002, India.
Author contributions:
V Sravan Reddy: Contributes towards concept, design, literature survey, experimental design, data and statistical analysis, manuscript preparation, editing & review.
I Sarath Chandra: Worked on, data and statistical analysis, manuscript preparation, editing & review
M Pramod Reddy: Contributes towards manuscript preparation, editing & review
CM Pavan Kumar Reddy: Contributes towards manuscript preparation, editing & review.
Core Idea: This is a cross sectional study conducted to assess the relationship between smoking and severity of illness in schizophrenia. 65.8% of our study sample was smokers. Smoking is significantly associated with elder age group patients, unemployment and higher mean scores on PANSS scale. There was a significant association between severity of smoking and higher mean scores on positive symptom domain and lower mean scores on negative symptom domains of PANSS, which indicate that smoking may, improves negative symptoms and worsens the positive symptoms in schizophrenia.
*Correspondence to:
Dr Vangala Sravan Reddy
Department of psychiatry,
Mamta General Hospital, Khammam, Andrapradesh-507002 India.
Contact number:+91-9849625869
Abstract:
Aims and objectives: To find out the prevalence of smoking in Schizophrenic patients and its association with socio demographic variables and severity of illness.
Method: The study was conducted in the outpatient department of Mamata General Hospital, Khammam, Andhra Pradesh in India, for a period of five months. All the patients were systematically interviewed and their socio-demographic details were noted. The diagnosis of schizophrenia was revised in accordance to ICD-10 RDC. Positive and Negative Syndrome Scale (PANSS) was used to assess the severity of the illness. Patients were divided into smokers and non smokers based on their current smoking status and patients who smoke were administered Fagerstrom Test for Nicotine Dependence (FTND) questionnaire to assess the severity of smoking.
Results: 65.8% of our study sample was smokers. A significant association was found between smoking and elder age group, unemployment and severity of schizophrenic symptoms. Patients who were severely dependent were found to be having higher mean scores on positive and general psychopathology subscales and lower mean scores on negative subscales of PANSS.
Conclusions: Findings suggests that there is a need for further longitudinal studies to assess the direct causality of smoking, weather beneficial or harmful in patients with schizophrenia.
Key words: Schizophrenia; Smoki ng; Severity; Psychopathology.
REFRENCES
1.WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package; World Health Organization: Geneva, Switzerland, 2008.
2.Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS. Med. 2006, 3, e442.
3.GATS. Global Adult Tobacco Survey; 2009-2010.
4.Chandra PS, Carey MP, Carey KB, Jairam KR, Girish NS, Rudresh HP. Prevalence and correlates of tobacco use and nicotine dependence am-ong psychiatric patients in India. Addict Behav 2005;30:1290-1299.
5.Neufeld KJ, Peters DH, Rani M, Bonu S, Brooner RK. Regular use of alcohol and tobacco in India and its association with age, gender, and poverty. Drug Alcohol Depend 2005;77:283-291.
6.Schizophrenia.NIH pub no 06-3517.Bethesda,Md, Us Department of Health and Human services.National institute Of Health ,2006
7.De Leon J, Dadvand M, Canuso C, White AO, Stanilla jK,Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152:453-455.
8.Etter M, Mohr S, Garin C, Etter JF. Stages of change in smokerswith schizophrenia or schizoaffecdve disorder and in the generalpopulation. Schizophr Bull 2004; 30:359-368.
9.De Leon , Diaz F. A meta-analysis of worldwide studiesdemonstrates an association between schizophrenia and tobaccosmoking behaviors. Schizophr Res 2005; 76:135-157.
10.De Leon J. Smoking and vulnerability for schizophrenia. Schizophrenia Bull. 1996; 22(3):405–409.
11.De Leon J, Becona E, Gurpegui M, Conzalea-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. JClin Psychiatry. 2002;63(9):812–816. [PubMed: 12363123]
12.Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986; 143(8):993–997. [PubMed: 3487983]
13.Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord. 2002; 1(2):149–162. [PubMed: 12769624].
14.Leonard S, Breese C, Adams C, et al. Smoking and schizophrenia: Abnormal nicotinic receptorexpression. Eur J Pharmacol. 2000; 393(1-3):237–242. [PubMed: 10771019]
15. Berlin I, Singleton EG, Pedarriosse AM, Lancrenon S, RamesA, Aubin HJ, Niaura R. The modified reasons for smokingscale: factorial structure, gender effects and relationship withnicotine dependence and smoking cessation in French smokers.Addiction 2003; 98:1575-1583.
16.Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotinedependence and schizophrenia. Hosp Community Psychiatry1994; 45:204-206.
17.Lyon ER. A review of the effects of nicotine on schizophreniaand antipsychotic medications. Psychiatr Serv 1999; 50:1346-1350.
18.Nomikos GG, Schilstorm B, Hiidebrand BE, Panagis G, GrenhoffJ, Sven'sson TH. Role of alpha 7 nicotine receptors in nicotinedependence and implications for psychiatric illness. Behav Brain Res 2000; 113:97-113.
19.Kumari V; Postma P. Nicotine use in schizophrenia: the selfmedication hypotheses.Neurosci Biobehav Rev 2005;29:1021-1034.
20.Lavin M, Siris S, Mason S. What is the clinical importance of cigarette smoking in schizophrenia? Am J Addict 1996;5:189-208.
21. Srinivasan TN, Thara R. Smoking in schizophrenia all is not biologi¬cal. Schizophr Res 2002;56:6774.
22.Saddichha S, Rekha DP, Patil BK, Murthy P, Benegal V, Isaac MK. Knowledge, attitude and practices of Indian dental surgeons towards tobacco control: advances towards prevention. Asian Pac J Cancer Prev 2010; 11:939-942.
23.Saddichha S, Khess CR. Prevalence of tobacco use among young adult males in India: a community-based epidemiological study. Am J Drug Alcohol Abuse 2010; 36:73-77.
24.Berlin I, Singleton EG, Pedarriosse AM, Lancrenon S, RamesA, Aubin HJ, Niaura R. The modified reasons for smokingscale: factorial structure, gender effects and relationship withnicotine dependence and smoking cessation in French smokers. Addiction 2003; 98(5):1575-1583.
24.WHO, International Classification of diseases-10 Research Diagnostic Criteria; 1992.
25.Kay SR,Fiszbein A, Opler LA.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
26.Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fager¬strom Test for Nicotine Dependence: a revision of the FagerstromtoleranceQuestionnaire. Br J Addict 1991; 86:1119-1127.
27.Kelly C, McCreadie RG. Smoking habits, current symptoms, and pre¬morbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156:1751-1757.
28.Xiang YT, Ma X, Lu JY et al. Alcohol-related disorders inBeijing, China: prevalence, sociodemographic correlates, andunmet need for treatment. Alcohol Clin Exp Res 2009; 33:1111–1118.
29.Sorensen G Gupta PC Pednekr MS.Social disparities in tobacco use in Mumbai:The roles of occupation ,education ,and gender .AMJ PUBLIC HEALTH.2005 JUNE ;95(6):1003-1008
30.Rajeev krishnadas,sameer jauhar,susan tefler,somashekara,shivashenkar.Nicotine dependence and illness severity in schizophrenia Bjp October 2012 201:306-312
31.Okan Ekinci,Asli Ekinci,.Dusunen Adam the journal of psychiatry and neurological sciences 2012;25(4). 285-296.
32.Van Dongen, C. J.). Smoking and persistent mental illness:An exploratory study. Journal of Psychosocial Nursing, 1999; 37 (11): 26–34.
33.Ziedonis, D. M. & George, T. P. Schizophrenia andnicotine use: report of a pilot smoking cessation program andreview of neurobiological and clinical issues. Schizophrenia
Bulletin, 1997; 23:247–254.
34.Forchuk, C., Norman, R., Malla, A., Vos, A. & Martin, M. L. Smoking and schizophrenia. of Psychiatricand Mental Health Journal Nursing, 1997; 4:355–359.
35.Dalack, G. W. & Meador-Woodruff, J. H. Smoking withdrawal and schizophrenia: case reports and areview of the literature. Schizophrenia Research, 1996; 22, 133–141.
36.Lohr, J. B. & Flynn, K.Smoking and schizophrenia. Schizophrenia Research, 1992; 8: 93–102.
Article citation:-
V Sravan Reddy, I Sarath Chandra, M Pramod Reddy,CM Pavan Kumar Reddy. Smoking and illness severity in schizophrenia. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1814-1819. Available at http: //www.jpbms.info
Copyright © 2013 V Sravan Reddy, I Sarath Chandra, M Pramod Reddy,CM Pavan Kumar Reddy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Debasis Das1,Kanti Bhushan Choudhury2,Sita Chattapadhyay3, Sougata Kumar Burman*4,Maitreyi Bandyopadhyay5, Abhijit Bhakta6
Affiliation:-
1Associate Professor, Community Medicine, Malda Medical College, Malda, West bengal,India.
2Assistant Professor, Community Medicine, Calcutta National Medical College, Kolkata,India.
3Associate Professor, Community Medicine, I.P.G.M.E.& R, Kolkata, India
4Clinical Tutor, Department of Obstetrics & Gynaecology, College of Medicine & J N M Hospital, WBUHS, Kalyani, Nadia, India.
5Assistant Professor, Department of Microbiology, R G Kar Medical College, Kolkata,India
6Associate Professor, Department of Anatomy R S Medical College, Kolkata, India
The name of the Department and Institution to which the work should be attributed:-
I C T C Centre
I P G M E & R
Kolkata
Author contributions:
All the authors equally to this paper.
*Correspondence to:
Dr Sougata Kumar Burman
Clinical Tutor
Obstetrics & Gynaecology.
College of Medicine & J N M Hospital,WBUHS.
Kalyni, West Bengal,.India.
Mobile: 09475943811
Abstract:
Objective: Recording the profile & queries of the clients attending Integrated Counselling & Testing Centre so that this information can be used for developing preparedness of the counsellor to handle questions of the clients in clinic. Design: It is a type of cross-sectional need assessment study. Setting: Counselling centre set-up of Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal. Method: All the 259 clients attending the ICTC centre during March – May’2011 were listened passively during group counselling followed by collection of selected client variable from the client records were done. Results: Among total 259 clients 36.68% were rural residents, others semi-urban or urban dwellers, 82.63% came referred from antenatal clinic & 13.51% from obstetrics & gynaecology clinic, mostly female, 97.37% in reproductive age group, mean age being 28.11±18.18 years, 7.45% illiterate & 97.3% married, 97.68% heterosexual, others being student and/or unmarried. No other risk factor like homosexuality, history of blood transfusion, history of use of infected syringe and needle in health facility found among any client. All clients are counselled, found HIV negative, 2.7% spouse tested. There are 75 different types of questions asked by 195 clients on general aspect of HIV /AIDS, transmission, prevention, treatment, tests and some unrelated areas. Among those who asked questions, 90.77percent able to comprehend the answer given by the counsellor, 58.97% found satisfied. Conclusion: To develop preparedness of the counsellor in ICTC, recording client queries is valuable.
Key words: Client, Queries; ICTC; India.
REFERENCES:
1.Operational Guidelines for Integrated Counselling and Testing Centres: National AIDS Control Organization. Ministry of Health & Family Welfare, Government of India, July 2007.
2.Olanrewjiu A M, Ola F A, Akintunde A E, Ibrahim B & Ibiyemi F. HIV voluntary counselling and testing of pregnant women in primary health care centres in Ilesa, Nigeria. The Internet Journal of Third World Medicine, 2007. Vol. 6 No. 1.
3.Pool R, Nyanzi S, Whitworth J A. Attitudes to voluntary counselling and testing for HIV among pregnant women in rural south-west Uganda. AIDS Care, 2001Oct; 13(5):605-15.
Article citation:-
Das Debasis et al. Queries of clients in integrated counselling & testing centre of a tertiary care hospital of West Bengal, India. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1826-1829. Available at http: //www.jpbms.info.
Copyright © 2013 Das Debasis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Soni Hardik K1*, Patel Vrushali V2, Vaghasiya Jitendra D2,
Patel Vandana B2, Patel Ghanshyam R1
Affiliation:-
1Vasu Research Centre, A Division of Vasu Healthcare Pvt. Ltd., 896/A, G.I.D.C., Makarpura, Vadodara – 390 010, Gujarat, India.
2Department of Pharmacology, Babaria Institute of Pharmacy, BITS Edu campus, Vadodara-Mumbai NH#8, Varnama, Vadodara – 391 240, Gujarat, India.
The name of the Department and Institution to which the work should be attributed:-
Vasu Research Centre, A Division of Vasu Healthcare Pvt. Ltd., 896/A, G.I.D.C., Makarpura, Vadodara – 390 010, Gujarat, India
Author contributions:
Soni Hardik K: Concept, design, literature search, data analysis and manuscript preparation.
Patel Vrushali V: Literature search, Experimental study, Data acquisition and Statistical analysis.
Vaghasiya Jitendra D and Patel Vandana B: Data analysis and manuscript review.
Patel Ghanshyam R: Data analysis and manuscript editing.
Core Idea: The study was initiated to evaluate safety and efficacy of anti-urolithiatic formulation developed from herbo-mineral source. Major ingredients of UCEX01 are individually well reported in Ayurvedic texts and scientific research publications for variety of activities like diuretic, anti-urolithiatic, anti-inflammatory etc. However, no such evidence was available which proves the safety and efficacy of such combination. Therefore, present study was taken up to evaluate acute toxicity and anti-urolithiatic activity of UCEX01.
*Correspondence to:
Soni Hardik K
Asst. Manager, R&D
Vasu Research Centre (A Division of Vasu Healthcare Pvt. Ltd.)
896/A, G.I.D.C., Makarpura, Vadodara-390010, Gujarat, India.
Tel.: 91-265-2657701, 2657702, Fax: 91-265-2647331
Mob.: 91-9428692240.
Abstract:
Urolithiasis is the most common urinary tract disorder with high recurrence. But, unfortunately most of its treatments are expensive or having side effects. Therefore, the search for anti-urolithiatic drugs from natural sources has been of great importance. UCEX01 is the herbo-mineral Ayurvedic formulation used for the treatment of kidney stone. But, no scientific evidences are available which proves safety and efficacy of such combination. Hence, present study was conducted to evaluate acute toxicity and anti-urolithiatic activity of UCEX01. Healthy male Wistar rats were used by dividing randomly into 4 groups. Group I was considered as normal control. Group II was as Disease control, Group III as UCEX01 treated with Therapeutic Effective Dose (TED-I) and Group IV was as UCEX01 treated with double of Therapeutic Effective Dose (TED-II). After 28th day, blood and urine sample were collected. Urine volume and pH was measured immediately. Bio-chemical parameters like calcium, phosphorus, creatinine and uric acid were estimated in serum and urine. Histopathology of kidney was also carried out. No mortality was observed during acute oral toxicity study. On basis of study data it can be concluded that the treatment of UCEX01 has significant anti-urolithiatic effect on ethylene glycol induced urolithiasis in rats. The underlying mechanism(s) of this effect is unknown however it may be attributed to its diuretic, anti-inflammatory and lowering of urinary concentrations of stone-forming elements. It can be a safe and effective remedy for the treatment of kidney stone.
Key words: UCEX01; ethylene glycol; urolithiasis; herbo-mineral Ayurvedic formulation.
REFERENCES
1.Silay MS and Miroglu C. The risk of urolithiasis recurrence may be reduced with anti-nanobacterial therapy. Med. Hypotheses. 2007; 68(6): 1348-50.
2.Mitra SK, Gopumodhavan S, Venkataranganna MV and Sundaran R. Effect of Cystone, an Herbal Formulation on Glycolic Acid - Induced Urolithiasis in Rats. Phytother Res. 1998; 12: 372-4.
3.Bashir S and Gilani A. Antiurolithic effect of Bergenia ligulata rhizome: An explanation of the underlying mechanism. J Ethnophamacol.2009; 112(1): 106-16.
4.Atmani F. Medical management of urolithiasis, what opportunity for phytotherapy? Frontiers in Bioscience 2003; 8: 507-14.
5.Misra A and Kumar Ashwani. Studies on Ayurvedic drugs for the cure of urinary tract stones. Journal of Indian Botanical Society 2000; 79 (Supplement): 47-8.
6.Anand R, Patnaik GK, Srivastava S, Kulshreshtha DK and Dhawan BN. Evaluation of anti-urolithiatic activity of Tribulus terrestris. Int. J. Pharmacog. 1994; 32(3): 217-24.
7.Sangeeta D, Sidhu H, Thind SK and Nath R. Therapeutic response of Tribulus terrestris (Gokhru) aqueous extract on hyperoxaluria in male adult rats. Phytother Res. 1993, 7: 116-9.
8.Joshi VS, Parekh BB, Joshi MJ. Herbal extracts of Tribulus terrestris and Bergenia ligulata inhibit growth of calcium oxalate monohydrate crystals in vitro. Journal of Crystal Growth 2009; 275(1-2): 1173-8.
9.Jarald EE, Kushwah P, Edwin S, Asghar S and Patni S. Effect of Unex on ethylene glycol-induced urolithiasis in rats. Indian J Pharmacol. 2011; 43(4): 466-8.
10.Pareta S, Patra K, Mazumder P and Sasmal D. Boerhaavia diffusa Linn aqueous extract as curative age¬nt i¬n ethyle¬ne glycol in¬duced urolithiasis. Pharmacologyonline 2010; 3: 112-20.
11.Sumankumar M, Satyaranjan M, Sabuj S and Prasanakumar P. Anti-urolithiatic activity of Crataeva bark. Indian Journal of Natural Products and Resources 2011; 2(1): 28-33.
12.Atanu Bhattacharjee, Shastry Chakrakodi Shashidhara and Aswathanarayana. Phytochemical and ethno-pharmacological profile of Crataeva nurvala Buch-Hum (Varuna): A review. Asian Pacific Journal of Tropical Biomedicine 2012, S1162-S1168.
13.Garimella TS, Jolly CI and Narayanan S. In Vitro studies on Antilitiatic Activity of seeds of Dolichos biflorus Linn. And Rhizomes of Begenia ligulata Wall. Phytother Res. 2001; 15: 351-5.
14.Bashir S and Gilani H. Antiurolithic effect of berberine is mediated through multiple pathways. European Journal of Pharmacology 2011; 651(1-3), 168-75.
15.Joyamma V, Rao SG, Hrishikeshavan HJ, Aroor AR, Kulkarni DR. Biochemical mechanisms and effects of Mimosa pudica (Linn) on experimental urolithiasis in rats. Indian J Exp Biol. 1990 Mar; 28(3):237-40.
16.Anonymous. Ayurved sar sangraha. published by Shri Bhaidyanath Ayurved Bhawan Pvt. Ltd., Nagpur, 2004: pp. 609.
17.Babar Vishal Bharat. Comparative Diuretic Study of Medicinal Plants in Individual and Combination Form. International Journal of Research in Pharmaceutical and Biomedical Sciences 2012; 3(4): 1432-35.
18.Shastri SD. Aryabhishak. Published by sastu sahitya vardhak karyalay, 2006: pp. 698.
19.Anonymous. Ayurved sar sangraha. published by Shri Bhaidyanath Ayurved Bhawan Pvt. Ltd., Nagpur, 2004: pp. 486.
20.Paget GE and Barnes JM. Evaluation of drug activities, In: Lawrence DR and Bacharach AL. Pharmacometrics. Vol.1, New York: Academic press; 1964, pp. 161.
21.OECD guideline. Guidance Document on Acute Oral Toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment No 24, 2000.
22.Verma NK, Patel SS, Saleem TSM, Christina AJM, Chidambaranathan N. Modulatory effect of noni-herbal formulation against ethylene glycol-induced nephrolithiasis in albino rats. Himalayan Pharmacy Institute, J. Pharm. Sci. & Res. 2009; 1(3): 83-9.
23.Runyan TJ and Gershoff SN. The effect of vitamin B6 deficiency in rats on the metabolism of oxalic acid precursors. J. Biol. Chem. 1965; 240: 1889-92.
24.Atef M. Al-Attar. Antilithiatic influence of spirulina on ethylene glycol-induced nephrolithiasis in male rats. American Journal of Biochemistry and Biotechnology 2010; 6(1): 25-31.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Article citation:-
Soni Hardik K, Patel Vrushali V, Vaghasiya Jitendra D, Patel Vandana B, Patel Ghanshyam R. Pharmacological evaluation of Anti-urolithiatic activity of UCEX01 - A herbo-mineral ayurvedic formulation. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1834-1839. Available at http: //www.jpbms.info.
Copyright © 2013 Soni Hardik K, Patel Vrushali V, Vaghasiya Jitendra D, Patel Vandana B, Patel Ghanshyam R. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sendhil Coumary1*,Seethesh Ghose2
Affiliation:-
1Associate Professor, Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute , Puducherry, India.
2Professor, Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute , Puducherry, India.
The name of the Department and Institution to which the work should be attributed:-
Department of Obstetrics & Gynaecology, Mahatma Gandhi Medical College and Research Institute , Puducherry, India.
Author contributions:
All the authors equally to this paper
Core Idea:
Maternal request caesarean delivery has sizeably added to the rising caesarean section rates of the present decade. Today’s women knowing their rights well demand caesarean delivery. The present study was aimed to know the attitude of obstetricians when they encountered such a situation.
*Correspondence to:
Dr.Sendhil Coumary
Associate Professor, Obstetrics and Gynaecology,
Mahatma Gandhi Medical College and Research Institute , Puducherry, India.
Abstract:
The aim of the study was to explore the attitude among obstetricians practising in South India to perform a caesarean section based only on maternal request. It was a cross-sectional study done among practising obstetricians with at least one year of experience following post graduate training. They were asked to reply to a pre-validated questionnaire with two imaginary case scenarios and their replies were analysed. The replies in both the scenarios were varying, as they tried to opt what they think is best for their patient and themselves. It showed that only a very small proportion of obstetricians were willing to perform a caesarean section based only on maternal request. The issue of caesarean section by maternal request remains a grey zone requiring more clarifications.
Key words: Caesarean section; Maternal request, Obstetrician’s attitude.
REFERENCES
1. Gabbe, Niebyl, Simpson Obstetrics normal and problem pregnancies 5th edition pg 486-517
2.Halvorsen L, Nerum H, Sørlie T, Oian P Halvorsen L, Nerum H, Sørlie T, Oian P Does counsellor's attitude influence change in a request for a caesarean in women with fear of birth? Midwifery.2010 Feb;26(1):45-52. Epub 2008 Jul 14 PMID: 18621452
3.Harris LH. Counselling women about choice. Best Pract Res ClinObstetGynaecol. 2001 Feb;15(1):93-107 PMID: 11359317
4. Habiba M, Kaminski M, Da Fre` M, Marsal K, Bleker O, Librero J, Grandjean H, Gratia P, Guaschino S, Heyl W, Taylor D, Cuttini M Caesarean section on request: a comparison of obstetricians’ attitudes in eight European countries. BJOG 2006; 113:647–656.
5.Ghetti C, Chan BK, Guise JM. Physicians' responses to patient requested caesarean delivery.Birth. 2004 Dec;31(4):280-4 PMID: 15566340
6.Advice on offering caesarean section in specific situations http://pathways.nice.org.uk/pathways/caesarean-section Pathway last updated: November 2012.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Source of support: Nil
Copyright © 2013 Coumary Sendhil,Ghose Seethesh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article citation:-
Coumary Sendhil,Ghose Seethesh. Maternal request caesarean delivery and the obstetrician’s attitude – A study. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1840-1843. Available at http: //www.jpbms.info.